• peji

Iyo Sinopharm COVID-19 yekudzivirira: Zvaunoda kuziva

Yakagadziridzwa musi wa10 Chikumi 2022, zvichienderana neyakagadziridzwa kurudziro yenguva pfupi.

WHO Strategic Advisory Group of Experts (SAGE) yakapa kurudziro yenguva pfupi yekushandiswa kweSinopharm yekudzivirira kurwisa COVID-19.Ichi chinyorwa chinopa pfupiso yezviya zvekurudziro zvenguva pfupi;unogona kuwana gwaro rekutungamira rakazara pano.

Hezvino zvaunofanira kuziva.

Ndiani anogona kubaiwa nhomba?

Mushonga wakachengeteka uye unoshanda kuvanhu vese vane makore gumi nemasere zvichikwira.Zvinoenderana neiyo WHO Prioritization Roadmap uye WHO Values ​​Framework, vakuru vakuru, vashandi vehutano uye vanhu vasina immunocompromised vanofanirwa kukoshesa.

Mushonga weSinopharm unogona kupihwa kune vanhu vanga vaine COVID-19 munguva yakapfuura.Asi vanhu vanogona kusarudza kunonoka kubayiwa kwemwedzi mitatu mushure mekutapukirwa.

Vakadzi vane pamuviri nevanoyamwisa vanofanira kubaiwa here?

Iyo data iripo paCCIDID-19 yekudzivirira yeSinopharm muvakadzi vane pamuviri haina kukwana kuongorora kana yekudzivirira kushanda kana njodzi dzine chekuita nekudzivirira pakubata pamuviri.Zvakadaro, jekiseni iri ijekiseni risingashandiswe rine adjuvant rinogaro shandiswa mune mamwe akawanda majekiseni ane chinyorwa chakanaka chekuchengetedza chimiro, kusanganisira mumadzimai akazvitakura.Kushanda kweCCIDID-19 yekudzivirira yeSinopharm muvakadzi vane nhumbu saka inotarisirwa kuenzaniswa neinocherechedzwa muvakadzi vasina nhumbu vezera rakafanana.

Munguva iyi, WHO inokurudzira kushandiswa kweCCIDID-19 yekudzivirira yeSinopharm muvakadzi vane pamuviri kana mabhenefiti ekudzivirira kumukadzi ane pamuviri achipfuura njodzi dzinogona kuitika.Kubatsira vakadzi vane pamuviri kuita ongororo iyi, vanofanirwa kupihwa ruzivo nezve njodzi yeCOVID-19 pakubata pamuviri;zvingangove zvinobatsira zvejekiseni munharaunda yenzvimbo yechirwere chetachiona;uye zvino zvisingakwanisi zvekuchengetedza data muvakadzi vane pamuviri.WHO haikurudziri kuongororwa kwepamuviri kusati kwabaya.WHO haikurudzire kunonoka kubata pamuviri kana kufunga kubvisa pamuviri nekuda kwejekiseni.

Kubudirira kwejekiseni kunotarisirwa kunge kwakafanana muvakadzi vanoyamwisa sevamwe vanhu vakuru.WHO inokurudzira kushandiswa kweCCIDID-19 yekudzivirira yeSinopharm muvakadzi vanoyamwisa sezvinoitwa nevamwe vanhu vakuru.WHO haikurudzire kurega kuyamwisa mushure mekudzivirira.

Nderipi jekiseni risingakurudzirwe?

Vanhu vane nhoroondo yeanaphylaxis kune chero chikamu chekudzivirira havafaniri kuitora.

Ani nani ane tembiricha yemuviri inodarika 38.5ºC anofanira kumbomira kubayiwa nhomba kusvika asisina kupisa.

Kwakachengeteka here?

SAGE yakanyatso ongorora iyo data pamhando, kuchengetedzeka uye kushanda kwejekiseni uye yakakurudzira kushandiswa kwayo kune vanhu vane makore gumi nemasere uye pamusoro.

Data yekuchengetedza inogumira kune vanhu vanopfuura makore makumi matanhatu ezera (nekuda kwenhamba shoma yevatori vechikamu mumakiriniki ekuyedzwa).Kunyange pasina misiyano yekuchengetedzwa kwemushonga wejekiseni muvakuru vakuru kana uchienzaniswa nemapoka ezera diki unogona kutarisirwa, nyika dziri kufunga nezvekushandisa jekiseni iri muvanhu vakura kupfuura makore makumi matanhatu dzinofanira kuramba dzichiongorora kuchengetedza.

Mushonga wekudzivirira unoshanda zvakadii?

Muyedzo wakakura wenyika dzakawanda Phase 3 wakaratidza kuti madosi maviri, anopihwa mukati memazuva makumi maviri nerimwe, ane 79% pakurwisa hutachiona hweSARS-CoV-2 mazuva gumi nemana kana kupfuura mushure mepiri yechipiri.Kushanda kwejekiseni pakurwisa kuchipatara kwaive 79%.

Muedzo uyu hauna kugadzirwa uye kupihwa simba rekuratidza kugona kurwisa chirwere chakakomba muvanhu vane comorbidities, pamuviri, kana muvanhu vane makore makumi matanhatu zvichikwira.Vakadzi vakanga vasingamiririrwi mukutongwa.Nguva yepakati yekutevera iripo panguva yekuongororwa kweuchapupu yaive mazuva 112.

Mimwe miedzo miviri yekushanda iri kuitika asi data haisati yavepo.

Ndeipi dosage inokurudzirwa?

SAGE inokurudzira kushandiswa kwejekiseni reSinopharm semadhosi maviri (0.5 ml) anopihwa intramuscularly.

SAGE inokurudzira kuti chetatu, yekuwedzera dhamo rekudzivirira kweSinopharm ripihwe kuvanhu vane makore makumi matanhatu zvichikwira sechikamu chekuwedzera kwekutanga.Yazvino data hairatidzi kudiwa kweimwe dosi muvanhu vari pasi pemakore makumi matanhatu.

SAGE inokurudzira kuti vanhu vakaomarara uye vane mwero hutachiona vanofanirwa kupihwa imwe dhamu yekudzivirira.Izvi zvinokonzerwa nekuti boka iri harina mukana wekupindura zvakaringana kugomarara zvichitevera chiyero chekutanga chekudzivirira uye vari panjodzi huru yechirwere cheCOVID-19.

WHO inokurudzira nguva yemavhiki 3-4 pakati pekutanga uye yechipiri dose yeprimary series.Kana iyo yechipiri dhizaini ichipihwa isingasviki mavhiki matatu mushure mekutanga, iyo dose haidi kudzokororwa.Kana kupihwa kwepiritsi yepiri kwakanonoka kupfuura mavhiki mana, inofanirwa kupihwa nekukurumidza.Pakupa imwe dosi kune vanopfuura makumi matanhatu, SAGE inokurudzira nyika dzinofanirwa kutanga dzakanangana nekuwedzera 2-dose kufukidzwa muhuwandu ihwohwo, uye zvozopa yechitatu dosi, kutanga nemapoka ezera rekare.

Mushonga webooster unokurudzirwa here pamushonga uyu?

A booster dose inogona kutariswa 4 - 6 mwedzi mushure mekupedzwa kweyekutanga vaccine nhevedzano, kutanga nepamusoro-soro-mapoka ekushandisa, zvinoenderana neWHO Prioritization Roadmap.

Mabhenefiti ekudzivirira kwebooster anocherechedzwa zvichitevera kuwedzera kwehumbowo hwekuderera kwekuita kwekudzivirira kubva kune hunyoro uye asymptomatic SARS-CoV-2 kutapukira nekufamba kwenguva.

Ingave homologous (yakasiyana yekudzivirira chigadzirwa kune Sinopharm) kana heterologous (a booster dose yeSinopharm) inogona kushandiswa.Chidzidzo muBahrain chakawana kuti heterologous boosting yakakonzera mhinduro yepamusoro yekudzivirira muviri kana ichienzaniswa nekuwedzera homologous.

Ko jekiseni iri rinogona 'kusanganiswa nekuenzaniswa' nemamwe majekiseni?

SAGE inogamuchira maviri heterologous madhizi eWHO EUL COVID-19 ekudzivirira senge akazara ekutanga akatevedzana.

Kuve nechokwadi chakaenzana kana chakanaka immunogenicity kana yekudzivirira kushanda ingave yeWHO EUL COVID-19 mRNA vaccines (Pfizer kana Moderna) kana iyo WHO EUL COVID-19 vectored vaccines (AstraZeneca Vaxzevria/COVISHIELD kana Janssen) inogona kushandiswa sechipiri dosi inotevera yekutanga dosi neSinopharm vaccine zvinoenderana nekuwanikwa kwechigadzirwa.

Inodzivirira utachiona uye kutapuriranwa here?

Parizvino hapana dhata rakakura riripo rine chekuita nekukanganisa kweSinopharm pakutapurirana kweSARS-CoV-2, hutachiona hunokonzera chirwere cheCOVID-19.

Zvichakadaro, WHO inoyeuchidza nezve kukosha kwekuchengetedza nekusimbisa hutano hweveruzhinji hunoshanda: masking, kufamba kure nemuviri, kugeza maoko, kufema uye kukosora hutsanana, kudzivirira mhomho uye kuve nemhepo yakakwana.

Inoshanda here kurwisa zvitsva zvakasiyana zveSARS-CoV-2 hutachiona?

SAGE parizvino inokurudzira kushandisa mushonga uyu, maererano neWHO Prioritization Roadmap.

Sezvo data idzva richiwanikwa, WHO inovandudza kurudziro zvinoenderana.Mushonga uyu hausati waongororwa mumamiriro ekutenderera kwezvakasiyana zvakasiyana zvekunetsekana.

Mushonga uyu unofananidzwa sei nemamwe majekiseni atove kushandiswa?

Hatigone kuenzanisa majekiseni musoro-ne-mumusoro nekuda kwenzira dzakasiyana dzakatorwa mukugadzira zvidzidzo, asi zvakazara, ese ekudzivirira awana WHO Emergency Use Listing anoshanda zvakanyanya mukudzivirira chirwere chakakomba uye kuchipatara nekuda kweCOVID-19. .


Nguva yekutumira: Jun-15-2022

  • Zvakapfuura:
  • Zvinotevera:

  •